195 related articles for article (PubMed ID: 10726041)
1. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome.
Walenga JM; Michal K; Hoppensteadt D; Wood JJ; Robinson JA; Bick RL
Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S76-84. PubMed ID: 10726041
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia.
Hoppensteadt DA; Walenga JM
Hematol Oncol Clin North Am; 2008 Feb; 22(1):1-18, v. PubMed ID: 18207062
[TBL] [Abstract][Full Text] [Related]
3. Newer insights on the mechanism of heparin-induced thrombocytopenia.
Walenga JM; Jeske WP; Prechel MM; Bakhos M
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():57-67. PubMed ID: 15085467
[TBL] [Abstract][Full Text] [Related]
4. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cell damage in heparin-induced thrombocytopenia.
Davidson SJ; Wadham P; Rogers L; Burman JF
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):317-20. PubMed ID: 17473571
[TBL] [Abstract][Full Text] [Related]
6. Systemic endothelial cell markers in primary antiphospholipid syndrome.
Williams FM; Parmar K; Hughes GR; Hunt BJ
Thromb Haemost; 2000 Nov; 84(5):742-6. PubMed ID: 11127848
[TBL] [Abstract][Full Text] [Related]
7. Heparin-induced thrombocytopenia associated with interleukin-8-dependent platelet activation in a patient with antiphospholipid syndrome.
Bounameaux C; Boehlen F; Membré A; Genné D; Pouplard C; Regnault V; de Moerloose P
Eur J Haematol; 2007 Dec; 79(6):550-3. PubMed ID: 17961179
[TBL] [Abstract][Full Text] [Related]
8. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function.
Gresele P; Migliacci R; Vedovati MC; Ruffatti A; Becattini C; Facco M; Guglielmini G; Boscaro E; Mezzasoma AM; Momi S; Pengo V
Thromb Res; 2009; 123(3):444-51. PubMed ID: 18617225
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies.
Jy W; Tiede M; Bidot CJ; Horstman LL; Jimenez JJ; Chirinos J; Ahn YS
Thromb Res; 2007; 121(3):319-25. PubMed ID: 17582471
[TBL] [Abstract][Full Text] [Related]
10. Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization.
Yeh RW; Everett BM; Foo SY; Dorer DJ; Laposata M; Van Cott EM; Jang IK
Am J Cardiol; 2006 Aug; 98(3):419-21. PubMed ID: 16860036
[TBL] [Abstract][Full Text] [Related]
11. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.
Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A
Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367
[TBL] [Abstract][Full Text] [Related]
12. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
Arnout J
Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
[TBL] [Abstract][Full Text] [Related]
13. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery.
Demir M; Duran E; Yigitbasi O; Vural O; Kurum T; Yuksel M; Turgut B; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):279-84. PubMed ID: 17636189
[TBL] [Abstract][Full Text] [Related]
14. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia.
Kwaan HC; Sakurai S
Semin Thromb Hemost; 1999; 25 Suppl 1():23-7. PubMed ID: 10357148
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory response and the endothelium.
Meroni PL; Borghi MO; Raschi E; Ventura D; Sarzi Puttini PC; Atzeni F; Lonati L; Parati G; Tincani A; Mari D; Tedesco F
Thromb Res; 2004; 114(5-6):329-34. PubMed ID: 15507262
[TBL] [Abstract][Full Text] [Related]
16. Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG.
Greinacher A; Liebenhoff U; Kiefel V; Presek P; Mueller-Eckhardt C
Thromb Haemost; 1994 May; 71(5):641-5. PubMed ID: 8091393
[TBL] [Abstract][Full Text] [Related]
17. Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.
Selleng K; Warkentin TE; Sheppard JA; Greinacher A
Transfusion; 2009 Sep; 49(9):1812-8. PubMed ID: 19497062
[TBL] [Abstract][Full Text] [Related]
18. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
19. P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment.
Papalambros E; Sigala F; Travlou A; Bastounis E; Mirilas P
J Am Coll Surg; 2004 Jul; 199(1):69-77. PubMed ID: 15217633
[TBL] [Abstract][Full Text] [Related]
20. Anti-beta2-glycoprotein I antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model.
Bourhim M; Darnige L; Legallais C; Arvieux J; Cevallos R; Pouplard C; Vijayalakshmi MA
J Mol Recognit; 2003; 16(3):125-30. PubMed ID: 12833567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
